Psoriatic Arthropathy
17 drugs35,405 FAERS reportsMedDRA PT
GET
/api/v1/reaction/psoriatic-arthropathyReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D015535
A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.
Source: U.S. National Library of Medicine — MeSH (Arthritis, Psoriatic)
Drugs reporting Psoriatic Arthropathy (17)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Triprolidine12244%
- 2Piroxicam81013%
- 3Diatrizoate6012%
- 4Calcium Gluconate1,23110%
- 5Neomycin5969.2%
- 6Bimekizumab1,3918.7%
- 7Brodalumab1598.2%
- 8Secukinumab9,9876.3%
- 9Certolizumab Pegol6,7865.9%
- 10Acitretin2835.9%
- 11Apremilast7,9585.5%
- 12Ustekinumab4,2624.2%
- 13Calcipotriene2493.8%
- 14Flurandrenolide113.5%
- 15Halobetasol402.7%
- 16Ixekizumab7662.1%
- 17Guselkumab6942.1%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
Literature
Recent PubMed references pinned to Arthritis, Psoriatic as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Multi-omics insights into spondyloarthritis and psoriatic arthritis: integrating genomics, transcriptomics, proteomics, and the microbiome for immunological and clinical translation.Frontiers in immunology · 2026 · Zhu M, Li R, Wu S, et al.PMID 42199404DOI 10.3389/fimmu.2026.1831823
- Genome-Wide Association Study of Psoriasis, Psoriatic Arthritis, Anti-TNF-α Response, and Polygenic Risk Score in a Russian Cohort.International journal of molecular sciences · 2026 · Karamova AE, Buianova AA, Vorontsova AA, et al.PMID 42196396DOI 10.3390/ijms27104422
- Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications.International journal of molecular sciences · 2026 · Totolici S, Vrabie AM, Buzea CA, et al.PMID 42196207DOI 10.3390/ijms27104226
- Central sensitization in rheumatoid arthritis and psoriatic arthritis is associated with symptom burden than inflammatory activity: a cross-sectional study.Rheumatology international · 2026 · Dilek G, Unan MK, Gokcen N, et al.PMID 42189297DOI 10.1007/s00296-026-06147-8
- Effect of an Online, Interactive Lifestyle Intervention Program on 12-Month Disease Management Outcomes: Protocol for The Healthy Living in Inflammatory Arthritis (HELIA) Randomized Controlled Trial.JMIR research protocols · 2026 · van Slingerland K, Wilmsen N, Coles E, et al.PMID 42184376DOI 10.2196/83749
- From Onset to Outcome: A Long-term Retrospective, Single centre Study of Guttate Psoriasis from Israel.Acta dermato-venereologica · 2026 · Kassem R, Edri N, Barzilai A, et al.PMID 42183773DOI 10.2340/actadv.v106.adv-2025-0112
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.